Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Non-Current Assets (2021 - 2025)

Stoke Therapeutics has reported Other Non-Current Assets over the past 5 years, most recently at $227000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 68.52% year-over-year to $227000.0; the TTM value through Dec 2025 reached $227000.0, down 68.52%, while the annual FY2025 figure was $227000.0, 68.52% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $227000.0 at Stoke Therapeutics, down from $721000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $721000.0 in Q4 2024 and troughed at $227000.0 in Q4 2025.
  • A 5-year average of $575823.5 and a median of $569000.0 in 2021 define the central range for Other Non-Current Assets.
  • On a YoY basis, Other Non-Current Assets climbed as much as 45.95% in 2025 and fell as far as 68.52% in 2025.
  • Year by year, Other Non-Current Assets stood at $569000.0 in 2021, then changed by 0.0% to $569000.0 in 2022, then changed by 0.0% to $569000.0 in 2023, then grew by 26.71% to $721000.0 in 2024, then tumbled by 68.52% to $227000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for STOK at $227000.0 in Q4 2025, $721000.0 in Q3 2025, and $721000.0 in Q2 2025.